Teleflex Continues Restructuring By Selling Hudson Respiratory Business To Medline
Medline will pay $286m in cash for Teleflex's oxygen and aerosol therapy, active humidification, and non-invasive ventilation devices as well as incentive spirometers. Those businesses yielded $139m in 2020 revenues, but do not fit into Teleflex's plan for the future.
You may also be interested in...
Z-Medica’s wound care products, led by its QuikClot Control+ hemostatic dressing, complement Teleflex’s existing line of products marketed to first responders and the military.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.